Live Breaking News & Updates on Clinical Development At Glaxosmithkline

Share this article
Share this article
WARRINGTON, Pa., Feb. 1, 2021 /PRNewswire/ Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced the appointment of Joseph Soffer, M.D., F.A.C.C., as Executive Director of Clinical Development, effective immediately.
We are thrilled to welcome Joe to lead our cardiovascular clinical development efforts at such an important  time for Windtree, said Dr. Steve Simonson, Chief Medical Officer at Windtree Therapeutics. Joe s expertise in cardiology and substantial experience with drug development in the pharmaceutical industry will be invaluable to our istaroxime program in acute heart failure, including our study in early cardiogenic shock. ....

Joseph Soffer , Steve Simonson , Clinical Development At Glaxosmithkline , Affairs At Merck , Prnewswire Windtree Therapeutics Inc , Windtree Therapeutics Inc , Rutgers University , Pritzker School Of Medicine , University Of Chicago , Clinical Development , Executive Director , Chief Medical Officer , Internal Medicine , Senior Medical Director , Associate Medical Director , Medical Affairs , Pritzker School , Nasdaq Capital , Windtree Therapeutics , Incentive Plan , Nasdaq Listing Rule , ஜோசப் சோப்பேர் , ஸ்டீவ் சைமன்சன் , மருத்துவ வளர்ச்சி இல் கிளாக்சோஸ்மித்க்லைன் , வாழ்க்கைத்தொழில்கள் இல் மெர்க் , வின்ட்ரீ சிகிச்சை இன்க் ,